Abbott Electrophysiology Leaders Highlight Current Portfolio, Give Glimpse of Potential PFA Device
In the latest episode of AbbottTalks, Abbott Cardiovascular’s leaders, Christopher Piorkowski, MD, DVP and chief medical officer, Electrophysiology, and Dan Kaiser, DVP of product development, Electrophysiology, delve into the vast landscape of electrophysiology and the comprehensive approach Abbott is taking towards atrial fibrillation (AFib) treatment.
by Device Talks | March 12, 2024
Angie Hillyard, Director of Engineering at Cretex Medical | CDT represented Cretex Medical as we sponsored this episode of AbbottTalks.
To view Angie Hillyard's video interview, click on the Device Talks image.
In the latest episode of AbbottTalks, Abbott Cardiovascular’s leaders, Christopher Piorkowski, MD, DVP and chief medical officer, Electrophysiology, and Dan Kaiser, DVP of product development, Electrophysiology, delve into the vast landscape of electrophysiology and the comprehensive approach Abbott is taking towards atrial fibrillation (AFib) treatment.
The conversation highlights a potentially innovative pulsed field ablation (PFA) technology and Abbott’s broader AFib portfolio, showcasing a commitment to revolutionizing cardiac arrhythmia management. While the Volt™ Pulsed Field Ablation System could represent a significant leap forward with its unique capabilities for creating precise and tissue-selective lesions, Piorkowski and Kaiser emphasize the diversity and depth of solutions Abbott is developing. This includes advancements in diagnostic tools, patient monitoring, and a range of therapeutic approaches designed to offer customized and effective treatment pathways for individuals with AFib.
By focusing on a holistic view of patient care, they discuss how Abbott aims to improve clinical outcomes through technological innovation and enhance patients’ quality of life by making treatments more accessible, reducing procedure times, and addressing the broad spectrum of needs within the electrophysiology community. With ongoing clinical trials and research, Abbott is positioned at the forefront of addressing the unmet needs in AFib management, underlining the company’s commitment to continuous innovation and patient-centered care.
Thank you to Cretex Medical for sponsoring this episode of AbbottTalks. For more information on how Cretex Medical works with medical device companies, visit www.cretexmedical.com.
The conversation highlights a potentially innovative pulsed field ablation (PFA) technology and Abbott’s broader AFib portfolio, showcasing a commitment to revolutionizing cardiac arrhythmia management. While the Volt™ Pulsed Field Ablation System could represent a significant leap forward with its unique capabilities for creating precise and tissue-selective lesions, Piorkowski and Kaiser emphasize the diversity and depth of solutions Abbott is developing. This includes advancements in diagnostic tools, patient monitoring, and a range of therapeutic approaches designed to offer customized and effective treatment pathways for individuals with AFib.
By focusing on a holistic view of patient care, they discuss how Abbott aims to improve clinical outcomes through technological innovation and enhance patients’ quality of life by making treatments more accessible, reducing procedure times, and addressing the broad spectrum of needs within the electrophysiology community. With ongoing clinical trials and research, Abbott is positioned at the forefront of addressing the unmet needs in AFib management, underlining the company’s commitment to continuous innovation and patient-centered care.
Thank you to Cretex Medical for sponsoring this episode of AbbottTalks. For more information on how Cretex Medical works with medical device companies, visit www.cretexmedical.com.
